TYVASO is the #1 prescribed prostacyclin medication for PAH.

Skip to main content
SELECT A CONDITION
PATIENT SUPPORT PROGRAM
SELECT A CONDITION
PATIENT SUPPORT PROGRAM
Background photo of air particle

ABOUT TYVASO

Breathe It In…
And Help Get Back to What
Really Matters Most

  • Quickly deliver medicine to the site of disease by inhaling TYVASO directly to your lungs
  • Reach your optimal dose quickly
  • Walk farther and stay more active with fewer symptoms
  • Take your medicine at home or on the go
  • Receive support throughout your treatment journey
Portrait of woman using the TYVASO Inhalation System. Portrait of woman using the TYVASO Inhalation System mobile version

Taking TYVASO

You can take TYVASO in 1 of 2 ways: TYVASO DPI (Dry Powder Inhaler) or the TYVASO nebulizer. Be sure to talk with your doctor about which one is right for you.

Read more about each device in the Patient Brochure

TYVASO Is Inhaled Directly to the Lungs

TYVASO works to open up blood vessels and help keep the blood flowing through your lungs.

How Soon Can I Expect to See Results?*

In a clinical study, people who added TYVASO to their PAH background therapy walked farther—improving their 6MWD† by 22 m at 12 weeks, with improvements seen in as soon as 6 weeks.‡

SEE RESULTS

*Individual results may vary.
†6-minute walk distance (6MWD) is a test to see how far you can walk in 6 minutes.
‡In the 12-week clinical study of TYVASO, people taking an oral PAH medicine (bosentan or sildenafil) completed a 6-minute walk test at the beginning and end of the study.

quotes
My specialist noticed that the numbers weren't where she wanted them to be. So, she suggested TYVASO DPI.”
– Bill, TYVASO DPI Patient
WATCH NOW

TYVASO Has 2 Device Options

TYVASO DPI and the TYVASO nebulizer.

SEE TYVASO DEVICES

TYVASO Support

United Therapeutics CaresTM provides you with ongoing, one-on-one education and support beginning on day one of your TYVASO journey.

GET STARTED WITH SUPPORT

IMPORTANT SAFETY
INFORMATION

Before you take TYVASO or TYVASO DPI, tell your healthcare provider about all of your medical conditions, including if you:

  • Have low blood pressure
  • Have or have had bleeding problems
EXPAND

IMPORTANT SAFETY
INFORMATION

COLLAPSE

Before you take TYVASO or TYVASO DPI, tell your healthcare provider about all of your medical conditions, including if you:

  • Have low blood pressure
  • Have or have had bleeding problems
  • Have asthma or chronic obstructive pulmonary disease (COPD)
  • Are pregnant or plan to become pregnant. It is not known if either product will harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if either product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Either product and other medicines may affect each other.

Especially tell your healthcare provider if you take:

  • Medicines used to treat high blood pressure or heart disease
  • Medicines that decrease blood clotting (anticoagulants)
  • Water pills (diuretics)
  • Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®)

What are the possible side effects of TYVASO or TYVASO DPI?

Both products can cause serious side effects, including:

  • Low blood pressure (symptomatic hypotension). If you have low blood pressure, either product may lower your blood pressure more.
  • Bleeding problems. Either product may increase the risk of bleeding, especially in people who take blood thinners (anticoagulants).

The most common side effects of both products are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking TYVASO or TYVASO DPI because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing.

You may report side effects to the FDA at 

You are now leaving the Tyvaso.com website

This link will take you to a site maintained by a third party who is solely responsible for the site’s content. Click CONTINUE to proceed or CLOSE to return to www.TYVASO.com.

CONTINUE
www.fda.gov/MedWatch

or call 1-800-FDA-1088.

What are TYVASO and TYVASO DPI?

TYVASO (treprostinil) Inhalation Solution and TYVASO DPI (treprostinil) Inhalation Powder are prescription medicines used in adults to treat:

  • Pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. TYVASO or TYVASO DPI can improve the ability to exercise. Your ability to exercise decreases 4 hours after taking TYVASO or TYVASO DPI. It is not known if TYVASO or TYVASO DPI is safe and effective in children under 18 years of age.
  • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), which is high blood pressure in the lungs due to inflammation and sometimes scarring in the lungs. TYVASO or TYVASO DPI can improve the ability to exercise.

The risk information provided here is not comprehensive. To learn more about TYVASO or TYVASO DPI, talk with your healthcare provider. Please see Full Prescribing Information for TYVASO or TYVASO DPI, Instructions for Use manuals for TD-100 and TD-300 TYVASO® Inhalation System and TYVASO DPI® Inhalation Powder, and additional information at www.TYVASO.com or call 1-844-UNITHER (1-844-864-8437).


TYVISIconSEP2024

DPI=dry powder inhaler; PAH=pulmonary arterial hypertension.

Drug Discard Program Privacy Policy Consumer Health Privacy Terms of Use Contact Us Site Map

TYVASO and TYVASO DPI are registered trademarks of United Therapeutics Corporation.

All other brands are trademarks of their respective owners. The makers of these brands are not affiliated with and do not endorse United Therapeutics or its products.

© 2024 United Therapeutics Corporation. All rights reserved. US/TYV/0798